[Federal Register: January 15, 2009 (Volume 74, Number 10)]
[Notices]
[Page 2598-2599]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr15ja09-109]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2008-N-0543]
Agency Information Collection Activities; Submission for Office
of Management and Budget Review; Comment Request; Waiver of In Vivo
Demonstration of Bioequivalence of Animal Drugs in Soluble Powder Oral
Dosage Form Products and Type A Medicated Articles
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing that a
proposed collection of information has been submitted to the Office of
Management and Budget (OMB) for review and clearance under the
Paperwork Reduction Act of 1995.
DATES: Fax written comments on the collection of information by
February 17, 2009.
ADDRESSES: To ensure that comments on the information collection are
received, OMB recommends that written comments be faxed to the Office
of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer,
FAX: 202-395-6974, or e-mailed to oira_submissions@OMB.eop.gov. All
comments should be identified with the OMB control number 0910-0575.
Also include the FDA docket number found in brackets in the heading of
this document.
FOR FURTHER INFORMATION CONTACT: Denver Presley, Jr.,Office of
Information Management (HFA-710), Food and Drug Administration, 5600
Fishers Lane, Rockville, MD 20857, 301-796-3793.
SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has
submitted the following proposed collection of information to OMB for
review and clearance.
Waiver of In Vivo Demonstration of Bioequivalence of Animal Drugs in
Soluble Powder Oral Dosage Form Products and Type A Medicated
Articles--21 CFR Part 514 (OMB Control Number 0910-0575)--Extension
The Center for Veterinary Medicine has written this guidance to
address a perceived need for agency guidance in its work with the
animal health industry. This guidance describes the procedures that the
agency recommends for the review of requests for waiver of in vivo
demonstration of bioequivalence for generic soluble powder oral dosage
form products and Type A medicated articles.
The Generic Animal Drug and Patent Term Registration Act of 1988
permitted the generic drug manufacturers to copy those pioneer drug
products that were no longer subject to patent or other marketing
exclusivity protection. The approval for marketing these generic
products is based, in part, upon a demonstration of bioequivalence
between the generic product and the pioneer product. This guidance
clarifies circumstances under which FDA believes the demonstration of
bioequivalence required by the statute does not need to be established
on the basis of in vivo studies for soluble powder oral dosage form
products and Type A medicated articles. The data submitted in support
of the waiver request are necessary to validate the waiver decision.
The requirement to establish bioequivalence through in vivo studies
(blood level bioequivalence or clinical endpoint bioequivalence) may be
waived for soluble powder oral dosage form products or Type A medicated
articles in either of two alternative ways. A biowaiver may be granted
if it can be shown that the generic soluble powder oral dosage form
product or Type A medicated article contains the same active and
inactive ingredient(s) and is produced using the same manufacturing
processes as the approved comparator product or article. Alternatively,
a biowaiver may be granted without direct comparison to the pioneer
product's formulation and manufacturing process if it can be shown that
the active pharmaceutical ingredient(s) (API) is the same as the
pioneer product, is soluble, and that there are no ingredients in the
formulation likely to cause adverse pharmacologic effects. For the
purpose of evaluating soluble powder oral dosage form products and Type
A medicated articles, solubility can be demonstrated in one of two
ways: (1) ``USP definition'' approach or (2) ``Dosage adjusted''
approach.
In the Federal Register of October 29, 2008 (73 FR 64338), FDA
published a 60-day notice requesting public comment on the information
collection provisions. No comments were received.
FDA estimates the burden of this collection of information as
follows:
[[Page 2599]]
Table 1.--Estimated Annual Reporting Burden for Water Soluble Powders\1\
----------------------------------------------------------------------------------------------------------------
No. of Annual Frequency Total Annual Hours per
Respondents per Response Responses Response Total Hours
----------------------------------------------------------------------------------------------------------------
Same 1 1 1 5 5
formulation/
manufacturing
process
approach
----------------------------------------------------------------------------------------------------------------
Same API/ 5 5 5 10 50
solubility
approach
----------------------------------------------------------------------------------------------------------------
Total burden hours 55
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
Table 2.--Estimated Annual Reporting Burden for Type A Medicated Articles\1\
----------------------------------------------------------------------------------------------------------------
No. of Annual Frequency of Total Annual Hours per
Respondents Responses Responses Response Total Hours
----------------------------------------------------------------------------------------------------------------
Same 2 2 2 5 10
formulation/
manufacturing
process
approach
----------------------------------------------------------------------------------------------------------------
Same API/ 10 10 10 20 200
solubility
approach
----------------------------------------------------------------------------------------------------------------
Total burden hours 210
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
The sources of the previous data are records of generic drug
applications over the past 10 years.
Dated: January 8, 2009.
Jeffrey Shuren,
Associate Commissioner for Policy and Planning.
[FR Doc. E9-782 Filed 1-14-09; 8:45 am]
BILLING CODE 4160-01-S